Dabogratinib Establishes Initial Activity in FGFR3-Altered NMIBC

Evidence Source-gap catch-up · Published September 9, 2026 · Discovery September 9, 2026 · Importance 4/5 · Direction Mixed Summary Tyra Biosciences reported initial open-label Phase II SURF302 results for oral dabogratinib in adults with FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer. At 60 mg once…